• 1
    Manstein D, Herron GS, Sink RK, Tanner H, Anderson RR. Fractional photothermolysis: A new concept for cutaneous remodeling using microscopic patterns of thermal injury. Lasers Surg Med 2004; 34: 426438.
  • 2
    Laubach HJ, Tannous Z, Anderson RR, Manstein D. Skin responses to fractional photothermolysis. Lasers Surg Med 2006; 38: 142149.
  • 3
    Dierickx CC, Khatri KA, Tannous Z, Childs JJ, Cohen RH, Erofeev A, Tabatadze D, Yaroslavsky IV. Micro-fractional ablative skin resurfacing with two novel erbium laser systems. Lasers Surg Med 2008; 40: 113123.
  • 4
    Tannous Z. Fractional resurfacing. Clin Dermatol 2007; 25: 480486.
  • 5
    Hantash BM, Vikramaditya PB, Chan KF, Zachary CB. Ex vivo histological characterization of a novel ablative fractional resurfacing device. Lasers Surg Med 2007; 39: 8795.
  • 6
    Hantash BM, Vikramaditya PB, Kapadia B, Rahman Z, Jiang K, Tanner H, Chan KF, Zachary CB. In vivo histological evaluation of a novel ablative fractional resurfacing device. Lasers Surg Med 2007; 39: 96107.
  • 7
    Lapidoth M, Yagima Odo ME, Odo LM. Novel use of erbium:YAG (2,940 nm) laser for fractional ablative photothermolysis in the treatment of photodamaged facial skin: A pilot study. Dermatol Surg 2008; 34: 10481053.
  • 8
    Chapas AM, Brightman L, Sukal S, Hale E, Daniel D, Bernstein JL, Geronemus RG. Successful treatment of acneiform scarring with CO2 ablative fractional resurfacing. Lasers Surg Med 2008; 40: 381386.
  • 9
    Weibel J, Beer K. Ablative fractional laser resurfacing for a third-degree burn. J Drugs Dermatol 2009; 8(3): 294297.
  • 10
    Hædersdal M. Fractional ablative CO2 laser resurfacing improves a thermal burn scar. J Eur Acad Dermatol Venereol (in press).
  • 11
    Elias PM, Menon GK. Structural and lipid biochemical correlates of the epidermal permeability barrier. Adv Lipid Res 1991; 24: 126.
  • 12
    Scheuplein RJ. Percutaneous absorption after twenty-five years: Or old wine in new wineskins. J Invest Dermatol 1976; 67: 3138.
  • 13
    Govil SK. Transdermal drug delivery systems. In: TyleP, editor. Drug delivery devices. Fundamentals and applications. New York: Marcel Dekker; 1988. pp 385420.
  • 14
    Morrow DI, Garland MJ, McParron PA, Woolfson AD, Donnelly RF. Innovative drug delivery strategies for topical photodynamic therapy using porphyrin precursors. J Environ Pathol Toxicol Oncol 2007; 26: 105116.
  • 15
    Benson HA. Transdermal drug delivery: Penetration enhancement techniques. Curr Drug Deliv 2005; 2: 2333.
  • 16
    Cross SE, Roberts MS. Physical enhancement of transdermal drug application: Is delivery technology keeping up with pharmaceutical development? Curr Drug Deliv 2004; 1: 8192.
  • 17
    Gerritsen MJP, Smits T, Kleinpenning MM, van de Kerkhof PCM, van Erp PEJ. Pretreatment to enhance protoporphyrin IX accumulation in photodynamic therapy. Dermatology 2009; 218: 193202.
  • 18
    Baron ED, Harris L, Redpath WS, Shapiro H, Hetzel F, Morley G, Bar-Or D, Stevens SR. Laser-assisted penetration of topical anesthetic in adults. Arch Dermatol 2003; 139: 12881290.
  • 19
    Fang JY, Lee WR, Shen SC, Fang YP, Hu CH. Enhancement of topical 5-aminolevulinic acid delivery by erbium:YAG laser and microdermabrasion: A comparison with iontophoresis and electroporation. Br J Dermatol 2004; 151: 132140.
  • 20
    Shen SC, Lee WR, Fang YP, Hu CH, Fang JY. In vitro percutaneous absorption and in vivo protoporphyrin IX accumulation in skin and tumors after topical 5-aminolevulinic acid application with enhancement using an Er:laser. J Pharm Sci 2006; 95(4): 929938.
  • 21
    Yun PL, Tachihara R, Anderson RR. Efficacy of erbium:yttrium-aluminium-garnet laser-assisted delivery of topical anesthetic. J Am Acad Dermatol 2002; 47: 542547.
  • 22
    Morton CA, McKenna KE, Rhodes LE. Guidelines on topical photodynamic therapy: Update. Br J Dermatol 2008; 159: 12451266.
  • 23
    Lange N. Pharmaceutical and biological considerations in 5-aminolevulinic acid in PDT. In: HamblinMR, PawelM, editors. Advances in photodynamic therapy. Basic, translational, and clinical. Norwood MA: Artec House; 2008. pp 5991.
  • 24
    Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: Basic principles and present clinical experience. J Photochem Photobiol B 1990; 6: 143148.
  • 25
    Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 1992; 14: 275292.
  • 26
    Juzeniene A, Juzenas P, Ma L-W, Iani V, Moan J. Topical application of 5-aminolevulinic acid, methyl 5-aminolevulinic acid and hexyl 5-aminolevulinate on normal human skin. Br J Dermatol 2006; 155: 791799.
  • 27
    Gibson SL, Havens JJ, Foster TH, Hilf R. Time-dependent intracellular accumulation of delta-aminolevulinic acid, induction of porphyrin synthesis and subsequent phototoxicity. Photochem Photobiol 1997; 65: 416421.
  • 28
    Sakamoto FH, Doukas A, Farinelli WA, Tannous Z, Anderson RR. Intradermal aminolevulinic acid photodynamic therapy (ALA-PDT). Lasers Surg Med 2007; 39(S19): 35. Abstract 85.
  • 29
    Martin A, Tope WD, Grevelink JM, Starr JC, Fewkes JL, Flotte T, Deutsch TF, Anderson RR. Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: Implications for photodynamic treatment. Arch Dermatol Res 1995; 287: 665674.
  • 30
    Sandberg C, Halldin CB, Ericson MB, Larkö O, Krogstad AL, Wennberg AM. Bioavailability of aminolevulinic acid and methylaminolevulinate in basal cell carcinomas: A perfusion study using microdialysis in vivo. Br J Dermatol 2008; 159: 11701176.
  • 31
    Kollias N, Stamatas GN. Optical non-invasive approaches to diagnosis of skin diseases. J Investig Dermatol Symp Proc 2002; 7: 6475.
  • 32
    Sakamoto FH, Wanner M, Farinelli WA, Doukas AG, Anderson RR. Aminolevulinic acid photodynamic therapy (ALA-PDT) delivered after ablative fractional resurfacing in an animal model. Lasers Surg Med 2009; 41(S21): 28. Abstract 79.
  • 33
    Rhodes LE, de Rie MA, Leifsdottir R, Yu RC, Bachmann I, Goulden V, Wong GA, Richard MA, Anstey A, Wolf P. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol 2007; 143: 11311136.
  • 34
    Braathen L, Szeimies R-M, Besset-Sebuin N, Bissonnette R, Foley P, Pariser D, Roelandts R, Wennberg AM, Morton CA. Guidelines on the use of photodynamic therapy for non-melanoma skin cancer: An international consensus. J Am Acad Dermatol 2007; 56: 125143.
  • 35
    Morton CA, MacKie RM, Whitehurst C, Moore JV, McColl JH. Photodynamic terapy for basal cell carcinoma: Effect of tumor thickness and duration of photosensitizer application on response. Arch Dermatol 1998; 134: 248249.
  • 36
    Donnelly RF, Morrow DI, McCarron PA, Woolfson AD, Morrissey A, Juzenas P, Juzeniene A, Iani V, McCarthy HO, Moan J. Microneedle-mediated intradermal delivery of 5-aminolevulinic acid: Potential for enhanced topical photodynamic therapy. J Control Release 2008; 129: 154162.
  • 37
    Trelles MA, Vélez M, Mordon S. Correlation of histological findings of single session Er:YAG skin fractional resurfacing with various passes and energies and the possible clinical implications. Lasers Surg Med 2008; 40: 174177.